Summary
According to DelveInsight’s estimates, nearly 580,000 prevalent cases of TGCT were reported across the 7MM in 2025, with approximately 460,000 cases classified as localized TGCT and nearly 120,000 as diffuse TGCT; these subtypes differ notably in clinical presentation, recurrence rates, and overall disease burden, and the total cases are expected to increase during the forecast period.
Despite being a rare condition, TGCT has attracted increasing interest from pharmaceutical companies due to its chronic nature and high unmet need, particularly in diffuse cases where surgery alone is often insufficient. Currently, limited systemic treatment options are a...
